Latin America Leukemia Therapeutics Market By Disease Condition (chronic Lymphatic Leukemia, Acute Lymphatic Leukemia, Chronic Myeloid Leukemia, Acute Myeloid Leukemia), By Diagnosis (CT Scan, Biopsy, MRI), By Treatments (chemotherapy, Radiation Therapy, Immunotherapy, Surgery, Targeted Therapy, Bone Marrow Transplant, Stem Cell Therapy), By Drugs (Gleevec, Sapacitabine, GA101, Vasaroxine, Tosedosat), And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018–2023)

Latin America Leukemia Therapeutics Market By Disease Condition (chronic Lymphatic Leukemia, Acute Lymphatic Leukemia, Chronic Myeloid Leukemia, Acute Myeloid Leukemia), By Diagnosis (CT Scan, Biopsy, MRI), By Treatments (chemotherapy, Radiation Therapy, Immunotherapy, Surgery, Targeted Therapy, Bone Marrow Transplant, Stem Cell Therapy), By Drugs (Gleevec, Sapacitabine, GA101, Vasaroxine, Tosedosat), And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018–2023)

ID: 826 | Pages: 145 | October 2018 | Region: Latin America


Latin America Leukemia Therapeutics market has been estimated at USD 0.67 Billion in 2018 and is projected to reach USD 1.12 Billion by 2023, at a CAGR of 10.7% during the forecast period from 2018 to 2023. Leukemia is a type of blood cancer resulting in the abnormal production of blood cells, generally white blood cells.  There are several types of leukemia that appear suddenly and progress rapidly over days to weeks. Others are less apparent and progress slowly over months to years. It can be identified by the spread of the diseases and by the type of the blood cell that is affected.

The market in Latin America for Leukemia Therapeutics is driving mainly due to factors like increasing geriatric population base and high prevalence of leukemia, along with increasing awareness in people regarding new treatments and drugs which is being made possible with recent breakthroughs. But the market growth can dip due to extremely high cost of drugs and therapies.

Latin America market for Leukemia Therapeutics is segmented based on disease condition, diagnosis, treatments and drugs. By disease condition, the market is further sub-segmented into chronic lymphatic leukemia, acute lymphatic leukemia, chronic myeloid leukemia and acute myeloid leukemia. By diagnosis, the market is further sub-segmented into CT scan, biopsy and MRI. By treatments, the market is further sub-segmented into chemotherapy, radiation therapy, immunotherapy, surgery, targeted therapy, bone marrow transplant and stem cell therapy. By drugs, the market is further sub-segmented into Gleevec, Sapacitabine, GA101, Vasaroxine, Tosedosat. By disease condition, chronic myeloid leukemia dominated the overall therapeutic market owing to high prevalence rate. Stem cell therapy and bone marrow transplant are the emerging trends in leukemia therapeutic market. Gleevec was the one of the major market growth contributors, in the drugs category.

Geographically, Latin America market for Leukemia Therapeutics is segmented into Brazil, Argentina and Mexico. Due to rising awareness for healthcare among the population in developing nations of this region, there is quite an increase in the penetration of companies into this segment, as well as regional market in Latin America.

F.Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited , Novartis International AG, Bristol-Myers Squibb , Eisai Co. Ltd, Biogen Idec , ERYtech Pharma , Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc. are the major players of Latin America Leukemia Therapeutics market.

1. Introduction                             

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods                       

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By Disease Condition                          

                             5.1.1 Chronic Lymphatic Leukemia         

                             5.1.2 Acute Lymphatic Leukemia             

                             5.1.3 Chronic Myeloid Leukemia             

                             5.1.4 Acute Myeloid Leukemia  

              5.2 By Diagnosis                           

                             5.2.1 CT scan    

                             5.2.2 Biopsy      

                             5.2.3 MRI          

              5.3 By Treatments                        

                             5.3.1 Chemotherapy     

                             5.3.2 Radiation therapy

                             5.3.3 Immunotherapy  

                             5.3.4 Surgery    

                             5.3.5 Targeted Therapy

                             5.3.6 Bone marrow transplant  

                             5.3.7 Stem Cell Therapy

              5.4 By Drugs                    

                             5.4.1 Gleevec    

                             5.4.2 Sapacitabine         

                             5.4.3 GA101      

                             5.4.4 Vasaroxine            

                             5.4.5 Tosedosat             

6. Geographical Analysis                                         

                             6.1 Introduction             

                             6.2 Brazil           

                             6.3 Mexico        

                             6.4 Rest of Latin America            

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8. Strategic Analysis                                   

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                    

              9.1 F. Hoffmann-La Roche Ltd                 

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                            9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 GlaxoSmithKline Pharmaceuticals Limited                  

              9.3 Novartis International AG                  

              9.4 Bristol-Myers Squibb                          

              9.5 Eisai Co. Ltd              

              9.6 Biogen Idec               

              9.7 ERYtech Pharma                    

              9.8 Celgene Corporation                           

              9.9 Genmab A/S                           

              9.10 Cephalon Inc.                       

              9.11 Clavis Pharma                      

              9.12 Pfizer Inc.                

10. Competitive Landscape                                     

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11. Expert Opinions                                   

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures                           

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Latin America Leukemia Therapeutics Market By Region, From 2018-2023 (USD Billion)
  2. Latin America Leukemia Therapeutics Market By Disease condition, From 2018-2023 (USD Billion)
  3. Latin America Cchronic Lymphatic Leukemia Market By Region, From 2018-2023 (USD Billion)
  4. Latin America Acute Lymphatic Leukemia Market By Region, From 2018-2023 (USD Billion)
  5. Latin America Chronic Myeloid Leukemia Market By Region, From 2018-2023 (USD Billion)
  6. Latin America Acute Myeloid Leukemia Market By Region, From 2018-2023 (USD Billion)
  7. Latin America Leukemia Therapeutics Market By Diagnosis, From 2018-2023 (USD Billion)
  8. Latin America Leukemia CT scan Market By Region, From 2018-2023 (USD Billion)
  9. Latin America Leukemia Biopsy Market By Region, From 2018-2023 (USD Billion)
  10. Latin America Leukemia MRI Market By Region, From 2018-2023 (USD Billion)
  11. Latin America Leukemia Therapeutics Market By Treatments, From 2018-2023 (USD Billion)
  12. Latin America Leukemia Chemotherapy Market By Region, From 2018-2023 (USD Billion)
  13. Latin America Leukemia Radiation Therapy Market By Region, From 2018-2023 (USD Billion)
  14. Latin America Leukemia Immunotherapy Market By Region, From 2018-2023 (USD Billion)
  15. Latin America Leukemia Surgery Market By Region, From 2018-2023 (USD Billion)
  16. Latin America Leukemia Targeted Therapy Market By Region, From 2018-2023 (USD Billion)
  17. Latin America Leukemia Bone marrow transplant Market By Region, From 2018-2023 (USD Billion)
  18. Latin America Leukemia Stem Cell Therapy Market By Region, From 2018-2023 (USD Billion)
  19. Latin America Leukemia Therapeutics Market By Drugs, From 2018-2023 (USD Billion)
  20. Latin America Leukemia Gleevec Market By Region, From 2018-2023 (USD Billion)
  21. Latin America Leukemia Sepecitabine Market By Region, From 2018-2023 (USD Billion)
  22. Latin America Leukemia GA101 Market By Region, From 2018-2023 (USD Billion)
  23. Latin America Leukemia Vasaroxine Market By Region, From 2018-2023 (USD Billion)
  24. Latin America Leukemia Tosedosat Market By Region, From 2018-2023 (USD Billion)
  25. Brazil Leukemia Therapeutics Market By Disease condition, From 2018-2023 (USD Billion)
  26. Brazil Leukemia Therapeutics Market By Diagnosis, From 2018-2023 (USD Billion)
  27. Brazil Leukemia Therapeutics Market By Treatments, From 2018-2023 (USD Billion)
  28. Brazil Leukemia Therapeutics Market By Drugs, From 2018-2023 (USD Billion)
  29. Argentina Leukemia Therapeutics Market By Disease condition, From 2018-2023 (USD Billion)
  30. Argentina Leukemia Therapeutics Market By Diagnosis, From 2018-2023 (USD Billion)
  31. Argentina Leukemia Therapeutics Market By Treatments, From 2018-2023 (USD Billion)
  32. Argentina Leukemia Therapeutics Market By Drugs, From 2018-2023 (USD Billion)
  33. Mexico Leukemia Therapeutics Market By Disease condition, From 2018-2023 (USD Billion)
  34. Mexico Leukemia Therapeutics Market By Diagnosis, From 2018-2023 (USD Billion)
  35. Mexico Leukemia Therapeutics Market By Treatments, From 2018-2023 (USD Billion)
  36. Mexico Leukemia Therapeutics Market By Drugs, From 2018-2023 (USD Billion)
Middle-East & Africa Cardiovascular Therapeutic Drugs By Disease (Arteriosclerosis, Cardiac Arrhythmias, Myocardial Infarction, Acute Coronary Syndrome, Peripheral Artery Disease, Coronary Artery Disease, Hypertensi...
Middle East And Africa Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail...
Latin America Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmaci...
Asia Pacific Clostridium Botulinum Market By Product (botulinum Toxin Type A And Botulinum Toxin Type B), By End User (aesthetic And Therapeutics), By Distribution Channel (hospitals, Clinics And Retail Pharmacies) ...
Europe Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmacies) And...
North America Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmaci...
Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmacies) And By Reg...
The Dental Bone Graft Substitutes Market Is Predicted To Reach USD 664.3 Million With A CAGR Of 9.8% According To Market Data Forecast Report....
Middle East And Africa Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal D...
Latin America Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Reg...
Asia-Pacific Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Rege...
Europe Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Regenerati...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2019 Market Data Forecast
All Rights Reserved.